Natixis Denali Therapeutics Inc. Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$20.88 - $35.19 $3.5 Million - $5.9 Million	-167,658 Reduced 70.84%	69,030 $2.03 Million
Q1 2022 May 13, 2022	SELL	$29.0 - $47.27 $1.65 Million - $2.69 Million	-56,866 Reduced 19.37%	236,688 $7.61 Million
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $609,037 - $786,786	14,300 Added 5.12%	293,554 $13.1 Million
Q3 2021 Nov 12, 2021	BUY	$48.48 - $78.23 $3.37 Million - $5.44 Million	69,556 Added 33.17%	279,254 $14.1 Million
Q2 2021 Aug 13, 2021	BUY	$50.3 - $78.44 $3.52 Million - $5.49 Million	70,000 Added 50.11%	209,698 $16.4 Million
Q1 2021 May 14, 2021	SELL	$53.8 - $81.53 $8.12 Million - $12.3 Million	-151,000 Reduced 51.94%	139,698 $7.98 Million
Q4 2020 Feb 12, 2021	BUY	$36.89 - $93.56 $9.77 Million - $24.8 Million	264,710 Added 1018.59%	290,698 $24.3 Million
Q3 2020 Nov 12, 2020	BUY	$23.13 - $38.84 $601,102 - $1.01 Million	25,988 New	25,988 $931,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.